The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study

被引:87
作者
Welles, Christine C. [2 ]
Whooley, Mary A. [2 ,3 ,4 ]
Na, Beeya [3 ]
Ganz, Peter [2 ,5 ]
Schiller, Nelson B. [2 ]
Turakhia, Mintu P. [1 ,6 ]
机构
[1] Stanford Univ, Dept Med Cardiovasc Med, Palo Alto, CA 94304 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[5] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA
[6] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA
关键词
CIRCULATING ENDOTHELIAL-CELLS; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; VOLUME; DYSFUNCTION; THROMBOEMBOLISM; SCHEMES; FAILURE; INDEXES;
D O I
10.1016/j.ahj.2011.05.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We sought to evaluate the prognostic performance of the CHADS(2) score for prediction of ischemic stroke/transient ischemic attack (TIA) in subjects with coronary heart disease (CHD) without atrial fibrillation (AF). Methods In 916 nonanticoagulated outpatients with stable CHD and no AF by baseline electrocardiogram, we calculated CHADS(2) scores (congestive heart failure, hypertension, age >= 75 years, diabetes [1 point each], and prior stroke or TIA [2 points]). The primary outcome was time to ischemic stroke or TIA over a mean follow-up of 6.4 +/- 2.3 years. Results Over 5,821 person-years of follow-up, 40 subjects had an ischemic stroke/TIA (rate 0.69/100 person-years, 95% CI 0.50-0.94). Compared with subjects with low (0-1) CHADS(2) scores, those with intermediate (2-3) and high (4-6) CHADS(2) scores had an increased rate of stroke/TIA, even after adjustment for age, tobacco, antiplatelet therapy, statins, and angiotensin inhibitors (CHADS(2) score 2-3: HR 2.4, 95% CI 1.1-5.3, P = .03; CHADS(2) score 4-6: HR 4.0, 95% CI 1.5-10.6, P = .006). Model discrimination (c-statistic = 0.65) was comparable with CHADS(2) model fit in published AF-only cohorts. Conclusions The CHADS(2) score predicts ischemic stroke/TIA in subjects with stable CHD and no baseline AF. The event rate in non-AF subjects with high CHADS(2) scores (5-6) was comparable with published rates in AF patients with moderate CHADS(2) scores (1-2), a population known to derive benefit from stroke prevention therapies. These findings should inform efforts to determine whether stroke prevention therapies or screening for silent AF may benefit subjects with stable CHD and high CHADS(2) scores. (Am Heart J 2011;162:555-61.)
引用
收藏
页码:555 / 561
页数:7
相关论文
共 40 条
  • [11] Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial
    Fitzmaurice, David A.
    Hobbs, F. D. Richard
    Jowett, Sue
    Mant, Jonathon
    Murray, Ellen T.
    Holder, Roger
    Raftery, J. P.
    Bryan, S.
    Davies, Michael
    Lip, Gregory Y. H.
    Allan, T. F.
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7616): : 383 - 386
  • [12] Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
    Furie, Karen L.
    Kasner, Scott E.
    Adams, Robert J.
    Albers, Gregory W.
    Bush, Ruth L.
    Fagan, Susan C.
    Halperin, Jonathan L.
    Johnston, S. Claiborne
    Katzan, Irene
    Kernan, Walter N.
    Mitchell, Pamela H.
    Ovbiagele, Bruce
    Palesch, Yuko Y.
    Sacco, Ralph L.
    Schwamm, Lee H.
    Wassertheil-Smoller, Sylvia
    Turan, Tanya N.
    Wentworth, Deidre
    [J]. STROKE, 2011, 42 (01) : 227 - 276
  • [13] ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
    Fuster, Valentin
    Ryden, Lars E.
    Cannom, David S.
    Crijns, Harry J.
    Curtis, Anne B.
    Ellenbogen, Kenneth A.
    Halperin, Jonathan L.
    Le Heuzey, Jean-Yves
    Kay, G. Neal
    Lowe, James E.
    Olsson, S. Bertil
    Prystowsky, Eric N.
    Tamargo, Juan Luis
    Wann, Samuel
    [J]. CIRCULATION, 2006, 114 (07) : E257 - E354
  • [14] Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation
    Gage, BF
    Waterman, AD
    Shannon, W
    Boechler, M
    Rich, MW
    Radford, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22): : 2864 - 2870
  • [15] GOLDSTEIN L, 2011, STROKE, V42, P227
  • [16] GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
  • [17] GREGORY YHL, 1997, AM J CARDIOL, V80, P1566
  • [18] Using CHADS2 backwards plus echo criteria to identify stroke patients who have occult intermittent atrial fibrillation
    Haft, Jacob I.
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (02)
  • [19] Echocardiographic and Clinical Risk Factors for Atrial Fibrillation in Hypertensive Patients With Ischemic Stroke
    Haft, Jacob I.
    Teichhoz, Louis E.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (10) : 1348 - 1351
  • [20] Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
    Hart, RG
    Benavente, O
    McBride, R
    Pearce, LA
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) : 492 - +